Cost-effectiveness analysis of the national Perinatal Hepatitis B Prevention Program

Pediatrics

Volumn 133, Issue 2, 2014, Pages 243-253

  Barbosa, Carolina ^a   Smith, Emily A ^b   Hoerger, Thomas J ^a   Fenlon, Nancy ^c   Schillie, Sarah F ^b   Bradley, Christina ^a   Murphy, Trudy V ^b  

^a RTI INTERNATIONAL   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

Author keywords

Cost; Cost effectiveness; Hepatitis B; Immunization programs; Infection; Perinatal; QALY

Indexed keywords

COST; COST-EFFECTIVENESS; HEPATITIS B; IMMUNIZATION PROGRAMS; INFECTION; PERINATAL; QALY;

COST-BENEFIT ANALYSIS; DECISION TREES; FEMALE; HEPATITIS B; HUMANS; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; NATIONAL HEALTH PROGRAMS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; QUALITY-ADJUSTED LIFE YEARS; UNITED STATES;

EID: 84893312958     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2013-0718     Document Type: Article

References (49)

1. Smith EA, Jacques-Carroll L, Walker TY, Sirotkin B, Murphy TV. The national Perinatal Hepatitis B Prevention Program, 1994-2008. Pediatrics. 2012;129(4):609-616
2. Margolis HS, Coleman PJ, Brown RE, Mast EE, Sheingold SH, Arevalo JA. Prevention of hepatitis B virus transmission by immunization. An economic analysis of current recommendations. JAMA. 1995;274(15):1201-1208
3. Beasley RP, Trepo C, Stevens CE, Szmuness W. The e antigen and vertical transmission of hepatitis B surface antigen Am J Epidemiol. 1977;105(2):94-98
4. Mast EE, Margolis HS, Fiore AE, et al; Advisory Committee on Immunization Practices (ACIP). A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep. 2005;54(RR-16):1-31
5. Goldstein ST, Zhou FJ, Hadler SC, Bell BP, Mast EE, Margolis HS. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol. 2005;34(6):1329-1339
6. Hutton DW, Tan D, So SK, Brandeau ML. Cost-effectiveness of screening and vaccinating Asian and Pacific Islander adults for hepatitis B. Ann Intern Med. 2007;147(7): 460-469
7. Pisu M, Meltzer MI, Lyerla R. Costeffectiveness of hepatitis B vaccination of prison inmates. Vaccine. 2002;21(3-4):312-321
8. Jacobs RJ, Saab S, Meyerhoff AS. The cost effectiveness of hepatitis immunization for US college students. J Am Coll Health. 2003; 51(6):227-236
9. Kim SY, Billah K, Lieu TA, Weinstein MC. Cost effectiveness of hepatitis B vaccination at HIV counseling and testing sites. Am J Prev Med. 2006;30(6):498-506
10. Krahn M, Guasparini R, Sherman M, Detsky AS. Costs and cost-effectiveness of a universal, school-based hepatitis B vaccination program. Am J Public Health. 1998;88(11):1638-1644
11. Drummond M, Sculpher M, Torrance G, O'Brien B, Stoddart G. Methods for the Economic Evaluation of Health Care Programmes. 3rd ed. Oxford, UK: Oxford University Press; 2005
12. Gold MR, Siegel JE, Russel LB, Weinstein MC. Cost Effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996
13. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making. 1993;13(4):322-338
14. Hunink M, Glaziou P, Siegel J, Weeks J, Pliskin J, Elstein A. Decision Making in Health and Medicine. Integrating Evidence and Values. Cambridge, UK: Cambridge University Press; 2001
15. Koumans EHA, Rosen J, van Dyke MK, et al; ABC and DHAP/RTI teams. Prevention of motherto-child transmission of infections during pregnancy: implementation of recommended interventions, United States, 2003-2004. Am J Obstet Gynecol. 2012;206(2):e1-, e11
16. Martin JA, Hamilton BE, Ventura SJ, et al. Births: final data for 2009. Natl Vital Stat Rep. 2011;60(1):1-70
17. Marion SA, Pastore MT, Pi DW, Mathias RG. Long-term follow-up of hepatitis B vaccine in infants of carrier mothers. Am J Epidemiol. 1994;140(8):734-746
18. Kohn MA, Farley TA, Scott C. The need for more aggressive follow-up of children born to hepatitis B surface antigen-positive mothers: lessons from the Louisiana Perinatal Hepatitis B Immunization Program. Pediatr Infect Dis J. 1996;15(6):535-540
19. Tharmaphornpilas P, Rasdjarmrearnsook AO, Plianpanich S, Sa-nguanmoo P, Poovorawan Y. Increased risk of developing chronic HBV infection in infants born to chronically HBV infected mothers as a result of delayed second dose of hepatitis B vaccination. Vaccine. 2009;27(44):6110-6115
20. Asian Liver Center. Hepatitis B statistics for Asians and Pacific Islanders. Stanford School of Medicine. Available at: http://liver. stanford.edu/Education/faq.html. Accessed September 9, 2012
21. Lin SY, Chang ET, So SK. Why we should routinely screen Asian American adults for hepatitis B: a cross-sectional study of Asians in California. Hepatology. 2007;46(4):1034-1040
22. Shuler CM, Fiore AE, Neeman R, et al. Reduction in hepatitis B virus seroprevalence among U.S.-born children of foreign-born Asian parents - benefit of universal infant hepatitis B vaccination. Vaccine. 2009;27 (43):5942-5947
23. Briggs A, Sculpher M, Klaxton C. Decision Modelling for Health Economic Evaluation. New York, NY: Oxford University Press; 2006
24. Grosse SD. Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold. Expert Rev Pharmacoecon Outcomes Res. 2008;8(2):165-178
25. Doubilet P, Begg CB, Weinstein MC, Braun P, McNeil BJ. Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach. Med Decis Making. 1985;5(2):157-177
26. Lee C, Gong Y, Brok J, Boxall EH, Gluud C. Hepatitis B immunisation for newborn infants of hepatitis B surface antigen-positive mothers. Cochrane Database Syst Rev. 2006;2006 (2):CD004790
27. Centers for Disease Control and Prevention (CDC). Estimated vaccination coverage for hepatitis B vaccine among children from birth to 3 days of age 2010. Available at: www2a.cdc.gov/nip/coverage/nis/nis-iap3.asp?fmt=v&rpt= tab03-antigen-state&qtr=Q1/2010-Q4/2010. Accessed September 4, 2012
28. Centers for Disease Control and Prevention (CDC). Estimated vaccination coverage for hepatitis B vaccine among children from birth to 3 days of age 2009. www2a.cdc.gov/nip/coverage/nis/nis-iap2.asp?fmt=v&rpt=tab03-antigen- state&qtr=Q1/2009-Q4/2009. Accessed September 4, 2012
29. Centers for Disease Control and Prevention (CDC). Estimated vaccination coverage with individual vaccines by 3 months of age 2010. Available at: www2a.cdc.gov/nip/coverage/nis/nis-iap3.asp?fmt=v&rpt=tab04-3mo-iap&qtr= Q1/2010-Q4/2010. Accessed September 4, 2012
30. Braithwaite RS, Meltzer DO, King JT Jr, Leslie D, Roberts MS. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Med Care. 2008;46(4):349-356
31. Neumann PJ, Weinstein MC. Legislating against use of cost-effectiveness information. N Engl J Med. 2010;363(16):1495-1497
32. Lee CF, Gong Y, Brok J, Boxall EH, Gluud C. Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systematic review and meta-analysis. BMJ. 2006;332(7537):328-336
33. Beasley RP, Hwang LY. Postnatal infectivity of hepatitis B surface antigen-carrier mothers. J Infect Dis. 1983;147(2):185-190
34. Schillie SF, Murphy TV. Seroprotection after recombinant hepatitis B vaccination among newborn infants: a review. Vaccine. 2013;31 (21):2506-2516
35. McMahon BJ, Dentinger CM, Bruden D, et al. Antibody levels and protection after hepatitis B vaccine: results of a 22-year follow-up study and response to a booster dose. J Infect Dis. 2009;200(9):1390-1396
36. Poovorawan Y, Chongsrisawat V, Theamboonlers A, et al. Evidence of protection against clinical and chronic hepatitis B infection 20 years after infant vaccination in a high endemicity region. J Viral Hepat. 2011;18(5): 369-375
37. Zhu C-L, Liu P, Chen T, et al. Presence of immune memory and immunity to hepatitis B virus in adults after neonatal hepatitis B vaccination. Vaccine. 2011;29(44): 7835-7841
38. Ott JJ, Stevens GA, Wiersma ST. The risk of perinatal hepatitis B virus transmission: hepatitis B e antigen (HBeAg) prevalence estimates for all world regions. BMC Infect Dis. 2012;12(1):131
39. Hwang LY, Roggendorf M, Beasley RP, Deinhardt F. Perinatal transmission of hepatitis-B virus - role of maternal HBeAg and anti-HBc IgM. J Med Virol. 1985;15(3): 265-269
40. Okada K, Kamiyama I, Inomata M, Imai M, Miyakawa Y, Mayumi M. e antigen and antie in the serum of asymptomatic carrier mothers as indicators of positive and negative transmission of hepatitis B virus to their infants. N Engl J Med. 1976;294(14): 746-749
41. Shiraki K, Yoshihara N, Sakurai M, Eto T, Kawana T. Acute hepatitis-B in infants born to carrier mothers with the antibody to hepatitis-B antigen. J Pediatr. 1980;97(5): 768-770
42. Stevens CE, Neurath RA, Beasley RP, Szmuness W. HBeAg and anti-HBe detection by radioimmunoassay - correlation with vertical transmission of hepatitis-B virus in Taiwan. J Med Virol. 1979;3(3):237-241
43. Centers for Disease Control and Prevention (CDC). CDC vaccine price list. 2012. Available at: www.cdc.gov/vaccines/programs/vfc/awardees/vaccine- management/price-list/index.html. Accessed September 4, 2012
44. Miriti MK, Billah K, Weinbaum C, et al. Economic benefits of hepatitis B vaccination at sexually transmitted disease clinics in the US. Public Health Rep. 2008;123(4): 504-513
45. Centers for Medicare & Medicaid Services. Fee schedule reimbursement rate. 2012. Available at: https://www.cms.gov/transmittals/downloads/R1209CP. pdf. Accessed September 4, 2012
46. Centers for Medicare & Medicaid Services. Clinical diagnostic laboratory fee (CLAB). 2012. Available at: www.cms.gov/Medicare/Medicare-Fee- for-Service-Payment/ClinicalLabFeeSched/index.html?redirect=/ ClinicalLabFeeSched/02-clinlab.asp. Accessed September 4, 2012
47. Centers for Medicare & Medicaid Services. Physician fee schedule. 2012. Available at: https://www.cms.gov/apps/physician-feeschedule/search/ search-criteria.aspx. Accessed September 4, 2012
48. Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ. 1997;6(4):327-340
49. Hoerger TJ, Wittenborn J, Uzunangelov V, Simpson S. Costs and Benefits Associated With Different Policy Approaches to Preventing and Controlling Viral Hepatitis: Final Report Prepared for the Department of Health and Human Services Office of the Assistant Secretary for Policy Evaluation. Research Triangle Park, NC: RTI International; 2012